'For
the quarter ending Dec 2023, consolidated Net sales (including other operating income) of Cipla has increased 13.66% to Rs 6603.81 crore compared to quarter ended Dec 2022. Sales of Phamaceuticals segment has gone up 13.89% to Rs 6,365.06 crore (accounting for 95.78% of total sales). Sales of New Ventures segment has gone down 10.17% to Rs 280.51 crore (accounting for 4.22% of total sales). Inter-segment sales came down from Rs 91.04 crore to Rs 41.76 crore. Profit before interest, tax and other unallocable items (PBIT) has jumped 35.91% to Rs 1,698.73 crore. PBIT of Phamaceuticals segment rose 35.58% to Rs 1,705.59 crore (accounting for 100.40% of total PBIT). PBIT of New Ventures segment rose 15.93% to Rs -6.86 crore (accounting for -0.40% of total PBIT).
PBIT margin of Phamaceuticals segment rose from 22.51% to 26.80%. PBIT margin of New Ventures segment rose from negat...
Pleaselogin & subscribe to view the full report.
More Reports
-
(17-Aug-2024)
AIA Engineering
Net down 5% on lower sales
-
(17-Aug-2024)
Voltas
Net jump 159% on good operating show
-
(17-Aug-2024)
ABB India
Net up 50% on good operating show
-
(17-Aug-2024)
NHPC
Sales down 2%, net down 1%
|
|